

# SCIENTIFIC REPORTS



OPEN

## Nicotine regulates activity of lateral habenula neurons via presynaptic and postsynaptic mechanisms

Wanhong Zuo<sup>1</sup>, Cheng Xiao<sup>1</sup>, Ming Gao<sup>2</sup>, F. Woodward Hopf<sup>3</sup>, Krešimir Krnjević<sup>4</sup>, J. Michael McIntosh<sup>5</sup>, Rao Fu<sup>1</sup>, Jie Wu<sup>2</sup>, Alex Bekker<sup>1</sup> & Jiang-Hong Ye<sup>1</sup>

Received: 05 May 2016  
Accepted: 12 August 2016  
Published: 06 September 2016

There is much interest in brain regions that drive nicotine intake in smokers. Interestingly, both the rewarding and aversive effects of nicotine are probably critical for sustaining nicotine addiction. The medial and lateral habenular (LHb) nuclei play important roles in processing aversion, and recent work has focused on the critical involvement of the LHb in encoding and responding to aversive stimuli. Several neurotransmitter systems are implicated in nicotine's actions, but very little is known about how nicotinic acetylcholine receptors (nAChRs) regulate LHb activity. Here we report in brain slices that activation of nAChRs depolarizes LHb cells and robustly increases firing, and also potentiates glutamate release in LHb. These effects were blocked by selective antagonists of  $\alpha 6$ -containing ( $\alpha 6^*$ ) nAChRs, and were absent in  $\alpha 6^*$ -nAChR knockout mice. In addition, nicotine activates GABAergic inputs to LHb via  $\alpha 4\beta 2$ -nAChRs, at lower concentrations but with more rapid desensitization relative to  $\alpha 6^*$ -nAChRs. These results demonstrate the existence of diverse functional nAChR subtypes at presynaptic and postsynaptic sites in LHb, through which nicotine could facilitate or inhibit LHb neuronal activity and thus contribute to nicotine aversion or reward.

Nicotine, a major bioactive component in tobacco that drives addiction to smoking, has both strong rewarding and aversive effects<sup>1</sup>. Although reward has been considered important for addiction, both effects may be critical for promoting smoking, since nicotine aversion can promote craving for nicotine and intake in addicted individuals<sup>1,2</sup>. It is well-known that nicotine reinforcement involves midbrain dopaminergic relays to nucleus accumbens<sup>3</sup>, but the circuitry mediating aversive effects is less clear. Several lines of evidence suggest that nicotine may induce reward and aversion through opposite actions on the mesolimbic system<sup>4,5</sup>. In addition, recent studies of aversion have focused on the lateral and medial habenula (LHb and MHb)<sup>1</sup>. The MHb is known to negatively regulate nicotine intake and contribute to nicotine aversion<sup>1,6–8</sup>. There is also much interest in the LHb; LHb neurons are activated by several aversive stimuli<sup>9,10</sup>, which in turn excites GABAergic neurons in the rostromedial tegmental nucleus (RMTg)<sup>9</sup> that inhibit midbrain dopaminergic neurons<sup>11,12</sup>. In this way, LHb could encode aversion to unpleasant stimuli<sup>13,14</sup> as well as nicotine aversion<sup>1,15</sup>. Although the LHb is critical for both nicotine reinstatement<sup>16</sup> and nicotine related anxiety<sup>15</sup>, little is known about the mechanisms through which nicotine regulates LHb neuronal activity. Previous work has shown that nicotine robustly excites RMTg neurons<sup>12</sup>, perhaps indirectly by stimulating the LHb.

Nicotine acts primarily through nicotinic acetylcholine receptors (nAChRs) composed of multiple subunits, which are present throughout the brain including in LHb<sup>17</sup> and MHb<sup>18</sup>. Studies from transgenic mice suggest that many nAChR subtypes can contribute to nicotine withdrawal, reinforcement and aversion<sup>1,19,20</sup>.  $\alpha 6^*$ -containing nAChRs in particular are highly expressed in mesolimbic pathways and mediate nicotine-related reward<sup>21–23</sup>, though the relevant brain locations have not been completely identified<sup>21,24,25</sup>. Given the prominent aversive effects of nicotine<sup>1</sup> and the LHb's importance for aversion, we used a combination of electrophysiology and pharmacology approach and  $\alpha 6^*$ -knockout mice to investigate whether different nAChRs contribute to nicotine modulation of LHb neuronal activity.

<sup>1</sup>Department of Anesthesiology, Pharmacology and Physiology, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, New Jersey, USA. <sup>2</sup>Divisions of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. <sup>3</sup>Department of Neurology, University of California at San Francisco, CA, USA. <sup>4</sup>Department of Physiology, McGill University, Montréal, Canada. <sup>5</sup>George E. Wahlen Veterans Affairs Medical Center and Departments of Psychiatry and Biology, University of Utah, Salt Lake City, UT, USA. Correspondence and requests for materials should be addressed to J.-H.Y. (email: ye@njms.rutgers.edu)

## Results

**Nicotine excites Lhb neurons.** As reported previously<sup>26,27</sup>, there is a clear border between the Lhb and the adjacent MHb (Figs 1A1 and 2). We thus distinguished the MHb and Lhb neurons according to the clear border. In addition, consistent with previous reports, we observed that Lhb neurons were loosely dispersed<sup>26</sup>, had heterogeneous morphological but similar membrane properties<sup>27</sup>, and were capable of producing burst firing<sup>26,28</sup>.

In the current study, we recorded from ~750 Lhb neurons. Nicotine increased firing in both cell-attached (Fig. 1B–D) and whole-cell modes (Fig. 1F). Nicotine accelerated spontaneous firing of 77/95 Lhb neurons in a dose-dependent manner, with an  $EC_{50}$  of 610 nM ( $F_{6,87} = 15.2$ ,  $p < 0.001$ ), and reached the plateau at 10  $\mu$ M (Fig. 1B–E). Interestingly, upon bath application of 100 nM nicotine, firing first decreased (to  $90.4 \pm 3.8\%$  of baseline,  $p < 0.05$ ; Fig. 1D), then sharply accelerated ( $p < 0.001$ ), returning to baseline level after washout (Fig. 1B–D). To confirm that the site of nicotine action was within the Lhb, recordings in a subset of experiments were made from slices with MHb removed (Fig. 1A3). Nicotine acceleration of Lhb neuron firings in these slices ( $F_{2,24} = 19.9$ ,  $p < 0.001$ ; *post hoc*  $p < 0.001$ , Fig. 1E blue triangle) was similar to that with MHb ( $p > 0.5$  with MHb vs without MHb).

In agreement with nicotine enhancement of firing, in the presence of tetrodotoxin (TTX), nicotine also dose-dependently depolarized Lhb neurons under current-clamp mode (Fig. 1F–H), with an  $EC_{50}$  of 410 nM ( $F_{6,37} = 8.2$ ,  $p < 0.001$ ; Fig. 1H). Similarly, nicotine induced inward currents (Fig. 1I) in 68/81 neurons under voltage-clamp at  $-70$  mV (in presence of blockers of sodium channels, GABA<sub>A</sub>, glycine, NMDA- and AMPA-type-glutamate receptors) which were dose-dependent ( $F_{6,73} = 27.5$ ,  $p < 0.001$ ; Fig. 1J) with an  $EC_{50}$  of 350 nM. Thus, nicotine depolarized Lhb neurons and increased their firing.

To identify nAChR subtypes that mediated nicotinic excitation of Lhb neurons, we examined the effects of several nicotine antagonists on nicotine-induced inward currents and on firing. Since 10  $\mu$ M nicotine produced the maximal effect on Lhb neuronal activity, we compared the peak amplitude of inward currents induced by 10  $\mu$ M nicotine in the absence and presence of various nAChR antagonists, which were applied for 5–8 min before co-applying nicotine or ACh. Nicotine currents were greatly reduced ( $F_{5,82} = 6.5$ ,  $p < 0.001$ , One-way ANOVA; Fig. 2A,C) by mecamylamine (MEC, 1  $\mu$ M,  $p = 0.002$ ), a non-selective nAChR antagonist,  $\alpha$ -CTx-MII (100 nM,  $p < 0.001$ ), an selective  $\alpha 6^*$  and  $\alpha 3\beta 2$ -nAChRs antagonist<sup>22,29</sup>, MII[H9A; L15A] (100 nM,  $p = 0.036$ ), an  $\alpha 6^*$ -nAChR blocker<sup>30</sup>, dihydro-beta-erythroidine (DH $\beta$ E, 100 nM,  $p = 0.006$ ), relatively selective for  $\alpha 4\beta 2$ -nAChRs, but not methyllycaconitine (MLA, 10 nM), an  $\alpha 7$ -nAChR antagonist ( $p > 0.5$ ). Thus,  $\alpha$ -CTx-MII-sensitive ( $\alpha 6^* - \pm \alpha 3\beta 2$ -) and DH $\beta$ E-sensitive ( $\alpha 4\beta 2$ ) nAChRs contributed to the nicotine-induced Lhb depolarization (Fig. 2C). In addition, although 10  $\mu$ M nicotine is higher than occurs physiologically in human smokers<sup>31</sup>, this concentration of nicotine was maximal and thus useful for determining in impact of different nAChR antagonists on nicotine modulation of different aspects of Lhb physiology.


We then examined the nAChR subtypes which mediated the nicotine enhancement of Lhb firing. Nicotine enhancement of firing was greatly attenuated by the nAChR antagonists tested above ( $F_{5,70} = 6.2$ ,  $p < 0.001$ ; Fig. 2B,D). *Post hoc* tests revealed substantial inhibition by MEC ( $p < 0.001$ ),  $\alpha$ -CTx-MII ( $p < 0.001$ ) and MII [H9A; L15A] ( $p = 0.001$ ), while DH $\beta$ E ( $p = 0.034$ ) and MLA ( $p = 0.049$ ) produced a smaller inhibition. Thus, MII-sensitive ( $\alpha 6^* - \pm \alpha 3\beta 2$ )-nAChRs played a prominent role in both the nicotine-induced firing enhancement (Fig. 2D) and membrane depolarization, while DH $\beta$ E-sensitive ( $\alpha 4\beta 2$ ) and MLA-sensitive ( $\alpha 7$ ) subtypes had partial and dissociable effects.

Apart from direct effects on Lhb neurons, bath-applied nicotine could act indirectly by stimulating cholinergic MHb neurons (~40% of which express  $\alpha 6^*$ -nAChR mRNA<sup>32</sup>) that project to the Lhb. To minimize indirect effects through MHb, we locally applied ACh (30  $\mu$ M) onto the somata of recorded Lhb neurons by pressure injection from a second micropipette<sup>33</sup>. In the presence of atropine, ACh induced an inward current ( $25.6 \pm 7.1$  pA) in 6/10 neurons tested ( $p = 0.005$ ) which was significantly depressed by MII [H9A; L15A] (to  $33.0 \pm 4.0\%$  of ACh,  $p = 0.016$ ; Fig. 2E). These experiments confirmed that there was a direct, MII [H9A; L15A]-sensitive nAChR (likely  $\alpha 6^*$ -nAChR)-mediated depolarization of Lhb cells. Indirect effects via MHb were also unlikely since nicotine depolarized Lhb cells (Figs 1F–H and 2A–D) in the presence of TTX and glutamate and GABA antagonists, which would block the corresponding synaptic inputs<sup>11,34,35</sup> from MHb neurons, and also because nicotine activated Lhb neurons in brain slices where MHb was cut off (Fig. 1E).


## Nicotine enhances synaptic potentials and currents (IPSCs and EPSCs) in Lhb neurons.

We next examined whether nicotine would alter inhibitory and excitatory post-synaptic currents (IPSCs and EPSCs, respectively) in Lhb neurons. We first examined how nicotine affects paired-pulse transmission when two PSCs were evoked at a brief inter-stimulus interval (50 msec). Nicotine (10  $\mu$ M) selectively enhanced the first IPSC of each pair (IPSC<sub>1</sub>;  $p < 0.05$ ; Fig. 3A,C), thus reducing the paired-pulse ratio (PSC<sub>2</sub>/PSC<sub>1</sub> = PPR) ( $p < 0.01$ ; Fig. 3D). Similarly, nicotine enhanced only EPSC<sub>1</sub> of each pair ( $p < 0.01$ ; Fig. 3B–D) and reduced the EPSC-PPR ( $p < 0.05$ ). Since decreased PPR can reflect increased transmitter release at the synapse, these results suggest that nicotine might potentiate synaptic transmission in Lhb by increasing presynaptic release of both glutamate and GABA.

To better understand the impact of nicotine on GABA and glutamate signaling in the Lhb, we then tested the effects of nicotine on spontaneous synaptic currents. Nicotine induced a transient shift to higher frequencies and larger amplitudes of spontaneous IPSCs (sIPSCs) (Fig. 3E–G), with an  $EC_{50}$  of 40 nM for frequency ( $F_{6,98} = 9.2$ ,  $p < 0.001$ ; Fig. 3N, black line) and 10 nM for amplitude ( $F_{6,98} = 3.9$ ,  $p = 0.002$ ; Fig. 3O, black line). By contrast, nicotine induced a slowly developing increase in spontaneous EPSC (sEPSC) frequency (Fig. 3H,I) with an  $EC_{50}$  of 140 nM ( $F_{6,105} = 8.9$ ,  $p < 0.001$ ; Fig. 3N, blue line), and a small but significant increase in sEPSC amplitude ( $p < 0.001$ , Kolmogorov-Smirnov test; Fig. 3J) with an  $EC_{50}$  of 210 nM ( $F_{6,105} = 4.9$ ,  $p < 0.001$ ; Fig. 3O, blue line). At a holding potential of  $-40$  mV, sEPSCs and sIPSCs appeared as distinct inward and outward currents, and nicotine (1  $\mu$ M) induced a transient outward current followed by a sustained inward current and increased frequency of sIPSCs and sEPSCs (Fig. 3K,M). Similar changes were seen under current clamp, with an initial hyperpolarization followed by depolarization and increased frequency of sIPSPs and sEPSPs (Fig. 3L,M). Thus, nicotine has




**Figure 1. Nicotine regulates LHb activity.** (A) Brain atlas diagram for approximate location of MHb and LHb (A1). Representative images of coronal slices containing the LHb with (A2) and without MHb (A3). (B–D) Nicotine first slowed and then accelerated LHb firing. Red arrow: initial firing reduction; (E) Concentration-response of nicotine-induced % increase of firing rate, recorded in cell-attached mode, in brain slices containing both LHb and MHb (●). Nicotine (1  $\mu$ M and 10  $\mu$ M) caused similar increases in firing rate of LHb neurons in brain slices with removed MHb ( $\Delta$ ). ns = no significance, with MHb vs without MHb. Number of neurons is indicated. Nicotine depolarization of LHb neurons (F), even in presence of TTX (G,H). (I,J) Nicotine-induced inward currents at a holding potential of  $-70$  mV, and in the presence of Inhibitor Cocktail. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , one-way ANOVA.




**Figure 2.** nAChR subtypes mediating nicotine effects in Lhb. (A) Nicotine-induced inward currents were blocked by MEC,  $\alpha$ -CTx-MII, MII[H9A; L15A] and DH $\beta$ E, but not MLA. (B) Nicotine-induced increases in firing rate was prominently reduced by MEC, and MII [H9A; L15A], and weakly but significantly reduced by MLA. (C,D) Summary of above data. (E) Local ACh application induced an MII [H9A; L15A]-sensitive inward current. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

a biphasic action in Lhb, causing a transient enhancement of ongoing GABA release and a slower but sustained increase in glutamate release.

We also examined the impact of nicotine on miniature synaptic currents, where spontaneous release was determined in the presence of TTX, Ca<sup>2+</sup>-free ACSF (where CaCl<sub>2</sub> was replaced by MgCl<sub>2</sub>) or in presence of 100  $\mu$ M




**Figure 3. Nicotine enhances IPSCs and EPSCs in LHB neurons.** (A,B) Nicotine action on paired evoked IPSCs (eIPSCs) (A) and evoked EPSCs (eEPSCs) (B). eIPSCs (recorded at V<sub>H</sub> = +40 mV) were abolished by gabazine (10  $\mu$ M), a GABA<sub>A</sub> receptor antagonist; eEPSCs (at V<sub>H</sub> = -70 mV) were abolished by DNQX (20  $\mu$ M), an AMPA receptor blocker. (C) Nicotine (10  $\mu$ M) enhanced the first of PSC pairs. (D) % change in amplitude (AMP) of first PSCs and paired pulse ratio (PPR = PSC<sub>2</sub>/PSC<sub>1</sub>). (E–J) Nicotine increased spontaneous sIPSC frequency and amplitude (E–G) as well as sEPSC frequency (H–J). (K,L) Simultaneous recording of sIPSC/sIPSPs and sEPSC/sEPSPs at -40 mV under voltage- (K) and current-clamp (L). (M) Different time course of nicotine action on the frequency of sIPSC/Ps and sEPSC/Ps (*n* = 9). (N,O) Concentration-dependence of increased sEPSC and sIPSC frequency (N) and amplitude (O). \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001.



**Figure 4.** Nicotine causes a smaller but significant increase in the frequency of spontaneous EPSCs (A1–3) and IPSCs (B1–3) in 0.5 μM TTX, in calcium free ACSF (extracellular Ca<sup>2+</sup> was replaced with Mg<sup>2+</sup>), and in 100 μM CdCl<sub>2</sub> (calcium channel blocker). (C,D) % increases in sEPSC and sIPSC frequency (C) and amplitude (D) induced by nicotine in the absence (ACSF) and presence of TTX, or calcium free ACSF, or CdCl<sub>2</sub>. ##  $p < 0.01$ , ###  $p < 0.001$ , Student's paired  $t$ -test for nicotine application vs pre-nicotine control. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , One-way ANOVA followed by Tukey's multiple comparison test for nicotine application vs nicotine plus TTX/calcium free ACSF/CdCl<sub>2</sub>.

cadmium chloride (CdCl<sub>2</sub>, a non-selective blocker of voltage-gated calcium channels). All of these treatments allow determination of the effects of nicotine on synaptic release in the absence of possible effects on presynaptic action potential generation (TTX) or activity-dependent effects on release (calcium-free or cadmium-containing media). Nicotine caused a smaller but still significant increase in the frequency of spontaneous miniature EPSCs ( $F_{3,77} = 5.8$ ,  $p = 0.001$ ; *post hoc*  $p = 0.004$ ) and IPSCs ( $F_{3,66} = 10.2$ ,  $p < 0.001$ ; *post hoc*  $p < 0.001$ ) in presence of TTX (Fig. 4A1,B1,C), in Ca<sup>2+</sup>-free ACSF (EPSC:  $p = 0.042$ ; IPSC:  $p < 0.001$ ; Fig. 4A2,B2,C) or in presence of CdCl<sub>2</sub> (EPSC:  $p = 0.014$ ; IPSC:  $p = 0.005$ ; Fig. 4A3,B3,C), when compared with the effects of nicotine on spontaneous release when presynaptic activity is allowed to occur. In addition, both miniature EPSC ( $F_{3,77} = 5.3$ ,  $p = 0.002$ ; Fig. 4D) or IPSC ( $F_{3,66} = 7.6$ ,  $p < 0.001$ ; Fig. 4D) amplitudes were significantly reduced in the presence of TTX (EPSC:  $p = 0.003$ ; IPSC:  $p < 0.001$ ) or Ca<sup>2+</sup>-free ACSF (EPSC:  $p = 0.046$ ; IPSC:  $p = 0.018$ ). These results are consistent with both presynaptic and postsynaptic actions of nicotine at excitatory and inhibitory synapses, increasing glutamatergic and GABAergic release, and that these actions depended in part on calcium channels.

We next examined the nAChR subtypes that mediate the nicotinic enhancement of spontaneous synaptic currents. Increased sIPSC frequency was greatly attenuated ( $F_{5,123} = 5.5$ ,  $p < 0.001$ ; Fig. 5A,C) by MEC ( $p < 0.001$ ) and DHβE ( $p < 0.001$ ) but not α-CTx-MII ( $p > 0.5$ ), MII[H9A; L15A] ( $p > 0.5$ ) or MLA ( $p = 0.28$ ). Antagonists had no effects when applied alone (data not shown). Thus, DHβE-sensitive (α4β2)-nAChRs but not α6\*-nAChRs



**Figure 5. nAChR subtypes mediating nicotine effects on sIPSCs and sEPSCs.** (A,B) Effects of various nAChR blockers on nicotine-induced acceleration of sIPSCs (A) and sEPSCs (B). (C) Summary of above data. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . (D) Proposed schematic of nAChR subtype distribution in the Lhb. (E,F) Nicotine enhanced firing (E) and mEPSC frequency (F) recorded in brain slices from wild-type (WT) but not  $\alpha 6$ -nAChR knock out ( $\alpha 6$  KO) mice. \* $p < 0.05$ , # $p < 0.05$ , ## $p < 0.01$ . (G) Summary of above data.

were important for mediating the nicotinic enhancement of sIPSC frequency. In contrast, the enhancement of sEPSC frequency was reduced ( $F_{5,132} = 7.4$ ,  $p < 0.001$ ; Fig. 5B,C) by MEC ( $p < 0.001$ ),  $\alpha$ -CTx-MII ( $p < 0.001$ ), MII[H9A; L15A] ( $p = 0.001$ ), less by MLA ( $p = 0.009$ ), but not significantly by DH $\beta$ E ( $p = 0.125$ ). Thus, MII-sensitive ( $\alpha 6^* \pm \alpha 3\beta 2$ )- and MLA-sensitive ( $\alpha 7$ )-nAChRs mediated nicotine's effects on glutamatergic inputs to Lhb neurons, similar to what was observed for the nicotine enhancement of Lhb firing (Fig. 2H).

**Increased firing and mEPSC frequency by nicotine are absent in  $\alpha 6$ -nAChR knock-out.** Since pharmacology experiments suggested that  $\alpha 6^*$ -nAChRs were critical for nicotine actions in the LHB (Fig. 2), we directly tested the importance of  $\alpha 6$ -nAChRs by comparing nicotine actions on LHB neurons from wild-type (WT) and  $\alpha 6$ -nAChR knock-out ( $\alpha 6$ -KO) mice. Compared to the WT mice, LHB neurons in the  $\alpha 6$ -KO mice exhibit higher basal firing rate (WT:  $6.6 \pm 1.4$  Hz,  $\alpha 6$ -KO:  $11.8 \pm 2.1$  Hz;  $p = 0.043$  WT vs KO) and basal mEPSC frequency (WT:  $1.0 \pm 0.1$  Hz;  $\alpha 6$ -KO:  $2.0 \pm 0.5$  Hz;  $p = 0.045$ ) but not basal mEPSC amplitude (WT:  $12.5 \pm 0.7$  pA;  $\alpha 6$ -KO:  $12.3 \pm 0.7$  pA;  $p = 0.84$ ). Importantly, nicotine ( $10 \mu\text{M}$ ) significantly increased LHB firing in WT but not  $\alpha 6$ -KO mutants ( $p = 0.03$  WT vs KO; Fig. 5E,G), and increased LHB mEPSC frequency in WT but not  $\alpha 6$ -KO mutants ( $p = 0.004$ ; Fig. 5F,G). These results directly demonstrate the importance of  $\alpha 6^*$ -nAChRs for the nicotine-induced enhancement of LHB activity. Alternatively, these results could reflect an occlusion of the ability of nicotine to increase firing in  $\alpha 6$ -KO mutants which have a higher basal firing rate.

**Mechanism of nicotine's biphasic action on LHB neurons.** As described in Fig. 1, upon the application of  $100 \text{ nM}$  nicotine, LHB firing was first decreased; and then sharply accelerated, returning to baseline after washout (Fig. 1A–C). We proposed that the decrease of firing was mediated by nicotinic potentiation of GABAergic transmission, and the enhancement of firing was mediated in part by nicotinic potentiation of glutamatergic transmission. To test this hypothesis, we compared the effects of  $100 \text{ nM}$  nicotine in the absence and presence of a GABA<sub>A</sub> receptor antagonist ( $20 \mu\text{M}$  gabazine), glutamate receptor antagonists ( $20 \mu\text{M}$  DNQX plus  $50 \mu\text{M}$  AP5), or a cocktail of both GABA<sub>A</sub> and glutamate receptor blockers (gabazine + DNQX + AP5).

As shown in Table 1, nicotine-induced inhibition of firing was completely abolished ( $F_{3,28} = 7.7$ ,  $p < 0.001$ ) by gabazine ( $p = 0.042$ ) or by the cocktail ( $p = 0.011$ ), but not by DNQX + AP5 ( $p > 0.5$ ). In contrast, nicotine-induced enhancement of firing was partly attenuated ( $F_{3,34} = 5.9$ ,  $p = 0.002$ ) by DNQX + AP5 ( $p = 0.013$ ) or by the cocktail ( $p = 0.04$ ), but not by gabazine alone ( $p > 0.5$ ). Thus, the ability of nicotine to increase and decrease firing was mediated by nicotine enhancement of IPSCs and EPSCs, respectively, although the excitatory effect of nicotine also involved mechanisms other than glutamate receptors.

## Discussion

Converging evidence indicates that the LHB is activated by aversive stimuli<sup>36</sup>. Nicotine can have strong aversive effects<sup>37</sup>, which can play an important role in promoting nicotine addiction<sup>1,2</sup>. In keeping with this, we found that nicotine strongly activated LHB neurons *in vitro*, as has been observed *in vivo*<sup>38</sup>; *in vivo*, LHB activation of RMTg neurons would in turn inhibit midbrain dopamine (DA) neurons and thus contribute to aversion<sup>12,39</sup>. In addition, we found that the actions of nicotine in LHB brain slice were mediated by distinct nAChR subtypes. Pharmacology and  $\alpha 6^*$ -knockout experiments suggested that  $\alpha 6^*$ -nAChRs played a prominent role in the sustained enhancement of LHB firing and glutamate release, while DH $\beta$ E-sensitive nAChRs, likely reflecting  $\alpha 4\beta 2$ -nAChRs, were important for the transient increase in GABAergic transmission. Our results show that different nAChR subtypes played a significant role in the regulation of LHB activity, which may contribute to both nicotine aversion and reward.

At different concentrations found in the blood of human smokers ( $25\text{--}444 \text{ nM}$ )<sup>31</sup>, nicotine acted at diverse nAChR subtypes to modulate LHB activity in brain slices from rats. Low concentrations ( $\text{EC}_{50}$   $20\text{--}50 \text{ nM}$ ) potentiated IPSCs via DH $\beta$ E sensitive ( $\alpha 4\beta 2$ ) nAChRs, leading to rapid but only brief hyperpolarization, consistent with  $\alpha 4\beta 2$ -nAChRs propensity to desensitization<sup>40–42</sup>. Higher nicotine concentrations ( $\text{EC}_{50}$   $\sim 200 \text{ nM}$ ) elicited a more sustained increase in glutamate release via MII-sensitive ( $\alpha 6^* \pm \alpha 3\beta 2$ )- and MLA-sensitive ( $\alpha 7$ )-containing nAChRs; pharmacology and knockout experiments combined suggest a particular role for  $\alpha 6^*$ -nAChRs in nicotine excitation of LHB neurons. Nicotine's actions on synaptic transmissions depended in part on calcium and TTX-sensitive sodium channels. At higher concentrations ( $\text{EC}_{50}$   $\sim 400 \text{ nM}$ ), nicotine directly depolarized LHB neurons via MII- and DH $\beta$ E-sensitive nAChRs but not by MLA-sensitive nAChRs. Similarly, the nicotine-induced increase in firing was sensitive to MII, MLA and DH $\beta$ E. The  $\text{EC}_{50}$  of nicotine for enhancing firing ( $\sim 600 \text{ nM}$ ) was about 1.5 fold greater than the  $\text{EC}_{50}$  of the nicotine-induced current responses. The difference between the  $\text{EC}_{50}$  for nicotine enhancement of firing and depolarization may reflect the presence of different nAChRs at presynaptic terminals versus postsynaptic neurons in LHB.

Genetic variations in the CHRNA6-CHRNA3 gene cluster increase vulnerability to tobacco smoking<sup>43–45</sup>.  $\alpha$ -CTx-MII infusion into  $\alpha 6^*$ -nAChRs-expressing mesolimbic regions (midbrain and nucleus accumbens)<sup>46–48</sup> decreases nicotine self-administration by rats<sup>21,25</sup>. Our findings show that the LHB is another critical brain region for  $\alpha 6^*$ -nAChR-mediated actions for nicotine. First, global disruption of  $\alpha 6$ -nAChRs increase basal mEPSC frequency as well as firing rate, indicating  $\alpha 6$ -nAChRs is a critical regulator of LHB neuronal activity. Second, although the MHB also expresses many nAChRs<sup>32</sup> and projects to LHB<sup>26</sup>, the effects we observed probably originated mainly in the LHB, since  $\alpha 6^*$ -mediated LHB currents were elicited by local applications of ACh or by bath applications of nicotine in the presence of TTX, and persisted when the MHB was cut away from the LHB. Moreover, nicotinic excitation of MHB neurons *in vitro*<sup>49</sup> does not require  $\alpha 6^*$ -nAChRs<sup>8</sup>. Previous immunoreactivity studies<sup>28</sup> suggest that  $\alpha 6$ -nAChRs are mainly expressed in the ventral inferior MHB, with little expression in the LHB. In the current study, using the patch-clamp electrophysiology technique, one of the most sensitive ways to detect functional activity of receptors, we were able to detect that nicotine modulated physiological activity of LHB neurons through action of nAChRs containing the  $\alpha 6$  subunit.

Nicotine has both negative and positive motivational effects which contribute to its abuse potential<sup>1</sup>. Here we demonstrate that nicotine, acting through  $\alpha 6^*$ -nAChRs, depolarizes LHB neurons and enhances glutamatergic signaling. Manipulating LHB activity, especially through  $\alpha 6^*$ -nAChRs, may therefore be of great value in treating nicotine addiction. In addition, we have shown that, over a wide range of concentrations ( $10 \text{ nM}\text{--}100 \mu\text{M}$ ), nicotine robustly activates LHB neurons. In contrast, nicotine at  $< 100 \text{ nM}$  has no significant effects on DA neurons in the ventral tegmental area (VTA); only at  $\geq 250 \text{ nM}$  does nicotine increase DA neuronal firing and burst

Nicotine-induced change of firing rate	ACSF	+Gabazine	+DNQX + AP5	+Gabazine + DNQX + AP5
Inhibition (% of baseline)	90.4 ± 3.8 (n = 8)	101.2 ± 1.0* (n = 8)	86.9 ± 3.5 (n = 8)	103.4 ± 2.5* (n = 8)
Excitation (% of baseline)	149.8 ± 7.3 (n = 14)	155.4 ± 6.8 (n = 8)	122.4 ± 3.5* (n = 8)	126.5 ± 3.9* (n = 8)

**Table 1. GABA or/and glutamate transmissions mediate nicotine-induced changes in firing of LHB neurons.** Nicotine (100 nM)-induced inhibition of spontaneous firing was abolished by the GABA<sub>A</sub> receptor antagonist gabazine, while nicotine-induced acceleration of firing was partly attenuated by glutamate receptor antagonists DNQX+AP5. \* $p < 0.05$ , One-way ANOVA followed by Tukey's multiple comparison test for nicotine application in ACSF vs nicotine plus these blockers.

activity<sup>50,51</sup>. Interestingly, once sufficient nicotine concentrations are reached, nicotine has a stronger effect on VTA-DA cells than on LHB neurons. For example, we found that nicotine at 1  $\mu$ M, a concentration within the range of peak blood levels in smokers, increased VTA-DA neuronal discharges by an average of  $2.32 \pm 0.4$  ( $n = 7$ ) fold *in vitro* (see also ref. 52). This is in agreement with other studies<sup>53</sup>, and was significantly greater than the  $1.52 \pm 0.07$  ( $n = 13$ ) fold increase in firing of LHB neurons ( $p = 0.017$ , unpaired  $t$ -test). Overall, the finding that nicotine at low concentrations activates LHB but not DA cells indicates that the LHB is exquisitely sensitive to the aversive effects of nicotine.

In addition to the LHB directly encoding aversive stimuli, activation of LHB neurons may contribute to aversion by inhibiting DA neurons indirectly via the RMTg<sup>54,55</sup>. Like the LHB, the RMTg is activated by aversive stimuli. Also, our findings that nicotine excites LHB glutamatergic neurons agree with recent studies showing that nicotine increases presynaptic glutamate release onto RMTg neurons<sup>12,39</sup>. Furthermore, a previous electrophysiological study in anesthetized rats showed that systemic administration of nicotine led to VTA-DA neuron activation which was preceded by a short-lasting inhibition<sup>56</sup>. We speculate that this inhibition of DA neurons could be caused by nicotine-induced excitation of LHB neurons, which activates the RMTg to inhibit DA cells. Emerging data also demonstrates that activation of the LHB-to-RMTg pathway induces acute avoidance<sup>9</sup>, and that activation of the Hb-IPN pathway reduces nicotine intake<sup>57</sup>. The Hb and its targets may also be important for symptoms of nicotine withdrawal, since inhibition of nAChRs in the Hb attenuates withdrawal symptoms<sup>6</sup>. In agreement, chronic nicotine exposure causes a hypodopaminergic state<sup>58</sup>, which may mediate the effects of nicotine withdrawal. Thus, reducing Hb-mediated inhibition of VTA DA neurons could be a useful strategy to relieve these withdrawal symptoms. These findings indicate that the LHB likely plays a critical role in different aspects of nicotine addiction.

Taken together, our data suggest that different subtypes of functional nAChRs are situated both presynaptically on local afferents innervating LHB neurons and postsynaptically on the somatodendritic regions of these neurons. By activating these receptors, nicotine likely enhance the output of LHB neurons and, in this way, contribute to the aversive properties of nicotine. Thus, direct nicotine action within the LHB via the pathways we have identified may represent a mechanism through which nicotine-related aversion could contribute to nicotine addiction.

## Methods

**Animals.** The Institutional Animal Care and Use Committee of Rutgers, Rutgers, the State University of New Jersey, and the Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, approved all procedures. All methods were performed in accordance with the relevant guidelines and regulations. Animals were housed under standard conditions at 22–24 °C, 50–60% humidity, and a 12 h light/dark cycle. For electrophysiological experiments, we used Sprague-Dawley rats (at postnatal days 20–40) and C57BL/6 (B6) mice [wild-type (WT) or nAChR  $\alpha 6$  subunit knock-out ( $\alpha 6$  KO) mice, at postnatal days 16–23]. As data obtained from either sex did not differ significantly, they were pooled.

**Brain slice preparation and electrophysiology.** Brain slices were prepared as described earlier<sup>59</sup>. Animals were anesthetized with ketamine/xylazine (80 mg/5 mg/kg i.p.) and then euthanized by decapitation. Coronal epithalamic slices (250  $\mu$ m) were cut in ice-cold glycerol-based artificial cerebrospinal fluid (GACSF) containing (in mM): 252 glycerol, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 1 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 25 NaHCO<sub>3</sub>, 0.3 L-ascorbate, and 11 glucose, and saturated with 95% O<sub>2</sub>/5% CO<sub>2</sub> (carbogen). Slices were then incubated >1-hr at 24–25 °C in carbogenated ACSF of similar composition as GACSF, but with 126 mM NaCl replacing glycerol. In a low Ca<sup>2+</sup> solution, CaCl<sub>2</sub> was replaced by an equivalent amount of MgCl<sub>2</sub>. The experiments were performed on slices in submerged in a chamber perfused with ACSF at ~33 °C, at 1.5–2 ml/min. Electrical signals were recorded using an Axon 200B or 700A amplifier and Clampfit 10.3 (Molecular Devices, Union City, CA), filtered at 2 kHz and sampled at 5 kHz. Patch pipettes (6–8 M $\Omega$ ) for voltage-clamp recordings contained (in mM): 140 Cs-methanesulfonate, 5 KCl, 2 MgCl<sub>2</sub>, 10 HEPES, 2 MgATP, 0.2 NaGTP, pH 7.2. The internal solution for current-clamp recordings was similar except that 140 mM K-gluconate replaced Cs-methanesulfonate. IPSCs were recorded at +40 mV in the presence of AP5 (50  $\mu$ M), DNQX (20  $\mu$ M) and strychnine (1  $\mu$ M) to block NMDA, AMPA and glycine receptors. EPSCs were recorded at –70 mV with strychnine (1  $\mu$ M) and gabazine (10  $\mu$ M) to block glycine and GABA<sub>A</sub> receptors. Miniature EPSCs were recorded in the presence of 0.5  $\mu$ M tetrodotoxin (TTX). PSCs were evoked with a bipolar nichrome electrode within 200  $\mu$ m from the recorded neurons, applying 100–200  $\mu$ s stimuli at 0.05 Hz. After obtaining an input/output curve, stimulation was set to a level eliciting 20–30% of maximal currents.

Spontaneous firing was recorded by the loose-patch cell-attached technique, allowing long-lasting recordings without perturbing the cytoplasmic contents, and in whole-cell mode to measure membrane potential and input resistance. Currents induced by nicotine or acetylcholine (ACh) were recorded in TTX, AP5, DNQX, gabazine, and strychnine. Compounds were applied by bath perfusion, except acetylcholine (30  $\mu$ M, with 0.5  $\mu$ M atropine to block muscarinic receptors) which was ejected by pressurized air from a micropipette placed near the recorded cell<sup>33</sup>.

**Drugs.** We purchased common salts and [L-1-methyl-2-(3-pyridyl) pyrrolidine] freebase (nicotine), 6,7-dinitroquinoxaline-2,3-dione (DNQX), DL-2-amino-5-phosphono-valeric acid (AP5), strychnine, mecamylamine hydrochloride, methyllycaconitine, gabazine, atropine, acetylcholine, CdCl<sub>2</sub>, TTX from Sigma (St Louis, MO), and dihydro- $\beta$ -erythroidine hydrobromide from Santa Cruz Biotechnology (Santa Cruz, CA).  $\alpha$ -conotoxin MII ( $\alpha$ -CTx-MII) and MII [H9A; L15A] were synthesized<sup>30</sup>.

**Data Analysis and Statistics.** Baseline electrophysiological data were recorded for 5–10 min, before drug superfusion and during the washout. To calculate the percent change in EPSCs/IPSCs/firing frequency or amplitude for a given cell, recordings during the initial control period were averaged and normalized to 100%. eIPSC and eEPSC amplitudes were calculated by averaging the peak current from six sweeps during baseline and during each drug application. For the measurement of inward currents induced by bath application of nicotine, traces were filtered at 10 Hz, and the means of 30-s baseline before nicotine application and 30 s during the maximal effects of nicotine were calculated and subtracted to give the magnitude of the nicotine current. The peak of nicotinic currents induced by puffing ACh onto neuronal somata was measured after the traces were filtered at 500 Hz. All values given in the text and figures indicate mean  $\pm$  S.E.M. Statistical significance was assessed by a two-tailed Student's *t* test, a one-way ANOVA with a Tukey's *post hoc* test for multiple group comparisons, or a Kolmogorov-Smirnov (K-S) test. Dose-response data were fitted to the logistic equation:  $y = 100x^\alpha / (x^\alpha + x_0^\alpha)$ , where *y* is the percentage change, *x* is the concentration of nicotine,  $\alpha$  the slope parameter, and *x*<sub>0</sub> the nicotine concentration which induces a half-maximal change.

## References

- Fowler, C. D. & Kenny, P. J. Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability. *Neuropharmacology* **76** Pt B, 533–544, doi: 10.1016/j.neuropharm.2013.09.008 (2014).
- Kenny, P. J. & Markou, A. Neurobiology of the nicotine withdrawal syndrome. *Pharmacol Biochem Behav* **70**, 531–549 (2001).
- Kenny, P. J. & Markou, A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. *Neuropsychopharmacology* **31**, 1203–1211, doi: 10.1038/sj.npp.1300905 (2006).
- Sun, N., Laviolette, S. R. & Addiction Research, G. Dopamine receptor blockade modulates the rewarding and aversive properties of nicotine via dissociable neuronal activity patterns in the nucleus accumbens. *Neuropsychopharmacology* **39**, 2799–2815, doi: 10.1038/npp.2014.130 (2014).
- Sellings, L. H., Baharnouri, G., McQuade, L. E. & Clarke, P. B. Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens. *Eur J Neurosci* **28**, 342–352, doi: 10.1111/j.1460-9568.2008.06341.x (2008).
- Salas, R., Sturm, R., Boulter, J. & De Biasi, M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. *J Neurosci* **29**, 3014–3018, doi: 10.1523/JNEUROSCI.4934-08.2009 (2009).
- Antolin-Fontes, B., Ables, J. L., Gorlich, A. & Ibanez-Tallon, I. The habenulo-interpeduncular pathway in nicotine aversion and withdrawal. *Neuropharmacology* **96**, 213–222, doi: 10.1016/j.neuropharm.2014.11.019 (2015).
- Gorlich, A. *et al.* Reexposure to nicotine during withdrawal increases the pacemaking activity of cholinergic habenular neurons. *Proc Natl Acad Sci USA* **110**, 17077–17082, doi: 10.1073/pnas.1313103110 (2013).
- Stamatakis, A. M. & Stuber, G. D. Activation of lateral habenula inputs to the ventral midbrain promotes behavioral avoidance. *Nat Neurosci* **15**, 1105–1107, doi: 10.1038/nn.3145 (2012).
- Lammel, S. *et al.* Input-specific control of reward and aversion in the ventral tegmental area. *Nature* **491**, 212–217, doi: 10.1038/nature11527 (2012).
- Hikosaka, O. The habenula: from stress evasion to value-based decision-making. *Nat Rev Neurosci* **11**, 503–513, doi: 10.1038/nrn2866 (2010).
- Lecca, S., Melis, M., Luchicchi, A., Muntoni, A. L. & Pistis, M. Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse. *Neuropsychopharmacology* **37**, 1164–1176, doi: 10.1038/npp.2011.302 (2012).
- Zuo, W. *et al.* Ethanol drives aversive conditioning through dopamine 1 receptor and glutamate receptor-mediated activation of lateral habenula neurons. *Addict Biol*, doi: 10.1111/adb.12298 (2015).
- Haack, A. K. *et al.* Lesions of the lateral habenula increase voluntary ethanol consumption and operant self-administration, block yohimbine-induced reinstatement of ethanol seeking, and attenuate ethanol-induced conditioned taste aversion. *Plos one* **9**, e92701, doi: 10.1371/journal.pone.0092701 (2014).
- Casarrubea, M. *et al.* Acute nicotine induces anxiety and disrupts temporal pattern organization of rat exploratory behavior in hole-board: a potential role for the lateral habenula. *Front Cell Neurosci* **9**, 197, doi: 10.3389/fncel.2015.00197 (2015).
- Khaled, M. A., Pushparaj, A., Di Ciano, P., Diaz, J. & Le Foll, B. Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking. *Neuropsychopharmacology* **39**, 3049–3058, doi: 10.1038/npp.2014.158 (2014).
- Larrauri, J. A., Burke, D. A., Hall, B. J. & Levin, E. D. Role of nicotinic receptors in the lateral habenula in the attenuation of amphetamine-induced prepulse inhibition deficits of the acoustic startle response in rats. *Psychopharmacology (Berl)* **232**, 3009–3017, doi: 10.1007/s00213-015-3940-z (2015).
- Zoli, M., Pistillo, F. & Gotti, C. Diversity of native nicotinic receptor subtypes in mammalian brain. *Neuropharmacology* **96**, 302–311, doi: 10.1016/j.neuropharm.2014.11.003 (2015).
- Drenan, R. M. & Lester, H. A. Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations. *Pharmacol Rev* **64**, 869–879, doi: 10.1124/pr.111.004671 (2012).
- Pang, X. *et al.* Habenula cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic acetylcholine receptors. *Neuropharmacology*, doi: 10.1016/j.neuropharm.2016.03.039 (2016).
- Brunzell, D. H., Boschen, K. E., Hendrick, E. S., Beardsley, P. M. & McIntosh, J. M. Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine. *Neuropsychopharmacology* **35**, 665–673, doi: 10.1038/npp.2009.171 (2010).

22. Jackson, K. J., McIntosh, J. M., Brunzell, D. H., Sanjakdar, S. S. & Damaj, M. I. The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. *J Pharmacol Exp Ther* **331**, 547–554, doi: 10.1124/jpet.109.155457 (2009).
23. Pons, S. *et al.* Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. *J Neurosci* **28**, 12318–12327, doi: 10.1523/JNEUROSCI.3918-08.2008 (2008).
24. Sanjakdar, S. S. *et al.* Differential Roles of alpha6beta2\* and alpha4beta2\* Neuronal Nicotinic Receptors in Nicotine- and Cocaine-Conditioned Reward in Mice. *Neuropsychopharmacology* **40**, 350–360, doi: 10.1038/npp.2014.177 (2015).
25. Gotti, C. *et al.* Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2\* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. *J Neurosci* **30**, 5311–5325, doi: 10.1523/JNEUROSCI.5095-09.2010 (2010).
26. Kim, U. & Chang, S. Y. Dendritic morphology, local circuitry, and intrinsic electrophysiology of neurons in the rat medial and lateral habenular nuclei of the epithalamus. *J Comp Neurol* **483**, 236–250, doi: 10.1002/cne.20410 (2005).
27. Weiss, T. & Veh, R. W. Morphological and electrophysiological characteristics of neurons within identified subnuclei of the lateral habenula in rat brain slices. *Neuroscience* **172**, 74–93, doi: 10.1016/j.neuroscience.2010.10.047 (2011).
28. Shih, P. Y. *et al.* Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula. *J Neurosci* **34**, 9789–9802, doi: 10.1523/JNEUROSCI.0476-14.2014 (2014).
29. Cartier, G. E. *et al.* A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. *J Biol Chem* **271**, 7522–7528 (1996).
30. McIntosh, J. M. *et al.* Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. *Mol Pharmacol* **65**, 944–952, doi: 10.1124/mol.65.4.944 (2004).
31. Russell, M. A., Jarvis, M., Iyer, R. & Feyerabend, C. Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. *Br Med J* **280**, 972–976 (1980).
32. Sheffield, E. B., Quick, M. W. & Lester, R. A. Nicotinic acetylcholine receptor subunit mRNA expression and channel function in medial habenula neurons. *Neuropharmacology* **39**, 2591–2603 (2000).
33. Engle, S. E., Broderick, H. J. & Drenan, R. M. Local application of drugs to study nicotinic acetylcholine receptor function in mouse brain slices. *J Vis Exp*, e50034, doi: 10.3791/50034 (2012).
34. Meye, F. J., Lecca, S., Valentinova, K. & Mamei, M. Synaptic and cellular profile of neurons in the lateral habenula. *Front Hum Neurosci* **7**, 860, doi: 10.3389/fnhum.2013.00860 (2013).
35. Lecca, S., Meye, F. J. & Mamei, M. The lateral habenula in addiction and depression: an anatomical, synaptic and behavioral overview. *Eur J Neurosci* **39**, 1170–1178, doi: 10.1111/ejn.12480 (2014).
36. Bromberg-Martin, E. S. & Hikosaka, O. Lateral habenula neurons signal errors in the prediction of reward information. *Nat Neurosci* **14**, 1209–1216, doi: 10.1038/nn.2902 (2011).
37. Laviolette, S. R. & van der Kooy, D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. *Nat Rev Neurosci* **5**, 55–65, doi: 10.1038/nrn1298 (2004).
38. Pierucci, M. *et al.* Lateral Habenula Contribution in Nicotine Addiction: Focus on Dopamine, GABA and Serotonin Interactions. *Malta Medical Journal* **3**, 6 (2011).
39. Lecca, S. *et al.* Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells. *Neuropsychopharmacology* **36**, 589–602, doi: 10.1038/npp.2010.190 (2011).
40. Ortells, M. O. & Arias, H. R. Neuronal networks of nicotine addiction. *Int J Biochem Cell Biol* **42**, 1931–1935, doi: 10.1016/j.biocel.2010.08.019 (2010).
41. Dani, J. A., Jenson, D., Broussard, J. I. & De Biasi, M. Neurophysiology of Nicotine Addiction. *J Addict Res Ther* **S1**, doi: 10.4172/2155-6105.S1-001 (2011).
42. Mansvelder, H. D. & McGehee, D. S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. *Neuron* **27**, 349–357 (2000).
43. Thorgeirsson, T. E. *et al.* Sequence variants at CHRN3-CHRNA6 and CYP2A6 affect smoking behavior. *Nat Genet* **42**, 448–453, doi: 10.1038/ng.573 (2010).
44. Hoft, N. R. *et al.* Genetic association of the CHRNA6 and CHRN3 genes with tobacco dependence in a nationally representative sample. *Neuropsychopharmacology* **34**, 698–706, doi: 10.1038/npp.2008.122 (2009).
45. Zeiger, J. S. *et al.* The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRN3) are associated with subjective responses to tobacco. *Hum Mol Genet* **17**, 724–734, doi: 10.1093/hmg/ddm344 (2008).
46. Le Novere, N., Zoli, M. & Changeux, J. P. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. *Eur J Neurosci* **8**, 2428–2439 (1996).
47. Quik, M., Polonskaya, Y., Gillespie, A., K Lloyd, G. & Langston, J. W. Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration. *Neuroscience* **100**, 63–72 (2000).
48. Champiaux, N. *et al.* Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. *J Neurosci* **23**, 7820–7829 (2003).
49. Dao, D. Q., Perez, E. E., Teng, Y., Dani, J. A. & De Biasi, M. Nicotine enhances excitability of medial habenular neurons via facilitation of neurokinin signaling. *J Neurosci* **34**, 4273–4284, doi: 10.1523/JNEUROSCI.2736-13.2014 (2014).
50. Yin, R. & French, E. D. A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: an *in vitro* electrophysiological study. *Brain Res Bull* **51**, 507–514 (2000).
51. Clark, A. & Little, H. J. Interactions between low concentrations of ethanol and nicotine on firing rate of ventral tegmental dopamine neurones. *Drug Alcohol Depend* **75**, 199–206, doi: 10.1016/j.drugalcdep.2004.03.001 (2004).
52. Liu, L., Zhao-Shea, R., McIntosh, J. M., Gardner, P. D. & Tapper, A. R. Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing alpha4 and alpha6 subunits. *Mol Pharmacol* **81**, 541–548, doi: 10.1124/mol.111.076661 (2012).
53. Chen, Y., Broad, L. M., Phillips, K. G. & Zwart, R. Partial agonists for alpha4beta2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects. *Br J Pharmacol* **165**, 1006–1016, doi: 10.1111/j.1476-5381.2011.01628.x (2012).
54. Balcita-Pedicino, J. J., Omelchenko, N., Bell, R. & Sesack, S. R. The inhibitory influence of the lateral habenula on midbrain dopamine cells: ultrastructural evidence for indirect mediation via the rostromedial mesopontine tegmental nucleus. *J Comp Neurol* **519**, 1143–1164, doi: 10.1002/cne.22561 (2011).
55. Brinschwitz, K. *et al.* Glutamatergic axons from the lateral habenula mainly terminate on GABAergic neurons of the ventral midbrain. *Neuroscience* **168**, 463–476, doi: 10.1016/j.neuroscience.2010.03.050 (2010).
56. Erhardt, S., Schwieler, L. & Engberg, G. Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. *Synapse* **43**, 227–237, doi: 10.1002/syn.10044 (2002).
57. Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J. & Kenny, P. J. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. *Nature* **471**, 597–601, doi: 10.1038/nature09797 (2011).
58. Koob, G. F. & Volkow, N. D. Neurocircuitry of addiction. *Neuropsychopharmacology* **35**, 217–238, doi: 10.1038/npp.2009.110 (2010).
59. Zuo, W., Chen, L., Wang, L. & Ye, J. H. Cocaine facilitates glutamatergic transmission and activates lateral habenular neurons. *Neuropharmacology* **70**, 180–189, doi: 10.1016/j.neuropharm.2013.01.008 (2013).

## Acknowledgements

We thank Dr. Michael J. Marks (Institute Behavior Genetics, Campus Box 447, University of Colorado) for kindly providing us with the  $\alpha 6$  nAChR knockout mice. Funded by NIH/NIAAA [AA021657, AA022292] and a grant from New Jersey Health Foundation to JHY and National Institute of General Medical Sciences [GM103801, GM48677] to JMM. We thank Dr. Hong Nie for advice on statistical analyses.

## Author Contributions

W.Z., C.X., M.G. and R.F. collected data, W.Z., J.-H.Y., C.X., F.W.H., K.K., X.F., W.H., J.W., A.B. and J.M.M. elaborated the study design and drafted the article. All authors critically reviewed content and approved final version for publication.

## Additional Information

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Zuo, W. *et al.* Nicotine regulates activity of lateral habenula neurons via presynaptic and postsynaptic mechanisms. *Sci. Rep.* **6**, 32937; doi: 10.1038/srep32937 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016